|
Name |
16-O-sulfo-18-norisopimar-7-en-4alpha,16-diol
|
| Molecular Formula | C19H32O5S | |
| IUPAC Name* |
2-[(2S,4aS,4bR,8R,8aR)-8-hydroxy-2,4b,8-trimethyl-3,4,4a,5,6,7,8a,9-octahydro-1H-phenanthren-2-yl]ethyl hydrogen sulfate
|
|
| SMILES |
C[C@@]1(CC[C@H]2C(=CC[C@@H]3[C@@]2(CCC[C@@]3(C)O)C)C1)CCOS(=O)(=O)O
|
|
| InChI |
InChI=1S/C19H32O5S/c1-17(11-12-24-25(21,22)23)10-7-15-14(13-17)5-6-16-18(15,2)8-4-9-19(16,3)20/h5,15-16,20H,4,6-13H2,1-3H3,(H,21,22,23)/t15-,16+,17+,18+,19+/m0/s1
|
|
| InChIKey |
MGAAHPXIGWJLPX-UURKPOQGSA-N
|
|
| Synonyms |
16-O-sulfo-18-norisopimar-7-en-4alpha,16-diol; Sulfuric acid 2-[(1R)-1alpha-hydroxy-1,4abeta,7-trimethyl-1,2,3,4,4a,4balpha,5,6,7,8,10,10aalpha-dodecahydrophenanthrene-7alpha-yl]ethyl ester
|
|
| CAS | NA | |
| PubChem CID | 102357825 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 372.5 | ALogp: | 3.3 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 92.2 | Aromatic Rings: | 3 |
| Heavy Atoms: | 25 | QED Weighted: | 0.559 |
| Caco-2 Permeability: | -5.04 | MDCK Permeability: | 0.00002100 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.053 | 20% Bioavailability (F20%): | 1 |
| 30% Bioavailability (F30%): | 0.6 |
| Blood-Brain-Barrier Penetration (BBB): | 0.086 | Plasma Protein Binding (PPB): | 93.16% |
| Volume Distribution (VD): | 1.154 | Fu: | 3.05% |
| CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.853 |
| CYP2C19-inhibitor: | 0.016 | CYP2C19-substrate: | 0.785 |
| CYP2C9-inhibitor: | 0.083 | CYP2C9-substrate: | 0.451 |
| CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.117 |
| CYP3A4-inhibitor: | 0.086 | CYP3A4-substrate: | 0.049 |
| Clearance (CL): | 2.809 | Half-life (T1/2): | 0.157 |
| hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.439 |
| Drug-inuced Liver Injury (DILI): | 0.028 | AMES Toxicity: | 0.025 |
| Rat Oral Acute Toxicity: | 0.014 | Maximum Recommended Daily Dose: | 0.898 |
| Skin Sensitization: | 0.732 | Carcinogencity: | 0.44 |
| Eye Corrosion: | 0.363 | Eye Irritation: | 0.841 |
| Respiratory Toxicity: | 0.981 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003257 | ![]() |
0.614 | D01CKY | ![]() |
0.269 | ||
| ENC005747 | ![]() |
0.560 | D0Z1XD | ![]() |
0.265 | ||
| ENC005750 | ![]() |
0.485 | D0Q6NZ | ![]() |
0.264 | ||
| ENC005748 | ![]() |
0.478 | D0L2LS | ![]() |
0.255 | ||
| ENC004729 | ![]() |
0.477 | D0U3GL | ![]() |
0.252 | ||
| ENC005749 | ![]() |
0.436 | D0IX6I | ![]() |
0.252 | ||
| ENC005751 | ![]() |
0.396 | D02CNR | ![]() |
0.250 | ||
| ENC001070 | ![]() |
0.382 | D08QKJ | ![]() |
0.248 | ||
| ENC002918 | ![]() |
0.365 | D0I2SD | ![]() |
0.248 | ||
| ENC002923 | ![]() |
0.353 | D0X4RS | ![]() |
0.246 | ||